United Kingdom (UK)
Recombinant monoclonal antibody to HIV-1/HIV-2 protease. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1696.
UniProt Accession Number of Target Protein: O90777
Alternative Name(s) of Target: HIV-1 PR; HIV-2 PR; HIV-1 protease; HIV-2 protease; HIV1 PR; HIV2 PR; HIV1 protease; HIV2 protease
Immunogen: 1696 was prepared by generating a hybridoma cell line, fusing myeloma cells with splenocytes derived from BALB/c mice immunized with HIV-1 PR in the presence of Freund's adjuvant.
Specificity: 1696 binds to HIV-PR of both HIV-1 and HIV-2 (IgG 1696: HIV-1 PR pH5.7 ~350 uM; pH7.4 ~100 nM - HIV-2 PR pH5.7 no measurable interaction; pH7.4 ~30 nM -- Fab 1696: HIV-1 PR pH5.7 ~410 nM; pH7.4 ~130 nM - HIV-2 PR pH5.7 no measureable interaction; pH7.4 ~40 nM-- determined by ELISA). The antibody binds to the N-terminal region of the enzyme, and binding is inhibited by the peptide fragment PQITLWQ which represents residues 1-7. Western blot binding assays show that 1696 recognizes the mature and processed form of the enzyme, but not the precursor which possesses 20 residues upstream from the cleavage site. The N-terminus has a well conserved structure between HIV-1 PR and HIV-2 PR. HIV-PR is a homodimeric apartate protease that specifically cleaves the viral Gag and Gag/Pol polyprotein precursor. A correlation has been observed between the activity of the protease and the degree of infectivity, and so this protein is a major antiviral target.
Application Notes: 1696 mAb can inhibit the catalytic activity of both HIV-1 and HIV-2 HIV-PR (1696 IgG HIV-1 PR IC50 ~0.6 nM; HIV-2 PR IC50 ~1.5 nM -- 1696 Fab HIV-1 PR IC50 ~1.1 nM; HIV-2 PR IC50 ~2.6 nM). Inhibition by 1696 is mediated by the destabilization of the of the active form of the active HIV-PR homodimer through binding to the N-terminus, which constitutes a large percentage of the interface between the monomers. The Fab fragment was generated by incubation of the antibody with pepsin. Binding constants of 1696 can be determined by ELISA. 1696 shows reactivity to the mature processed HIV-PR and not to the precursor by WB.
Antibody first published in:
Lescar et al. Inhibition of the HIV-1 and HIV-2 proteases by a monoclonal antibody Protein Sci. 1999 Dec; 8(12): 2686–2696. PMID:
Note on publication:
Describes the generation of the mAb 1696, its functional characterization and the determination of the crystal structure of the Fab fragment.